Class summary at a glance.

Every drug in the Guanylate Cyclase-C Agonist class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 2tracked in Part D
CY24 Part D spend: $3.26Bcombined across class
Total Rx claims: 4.0M1.2M unique beneficiaries
Generic mfrs (active): 0across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Linaclotide

Brand: Linzess · 3.8M Part D claims (CY24) · 1.1M beneficiaries · First FDA approval: 2012-09-08

Brand-only (no generics) 3 plans require PA

Low NADAC$9.02

→

Avg plan cost$9.03

Part D spend $3.07B 1× spread, current vs floor

Class share

94%

of class CY24 spend

View profile →

Plecanatide

Brand: Trulance · 229K Part D claims (CY24) · 75K beneficiaries · First FDA approval: 2017-02-21

Brand-only (no generics) 1 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $183.4M

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.